Navigation Links
Aerovance Appoints Babatunde A. Otulana, M.D., as Chief Medical Officer
Date:2/9/2009

BERKELEY, Calif., Feb. 9 /PRNewswire/ -- Aerovance Inc. today announced the appointment of Babatunde A. Otulana, M.D., to the position of senior vice president and chief medical officer.

Dr. Otulana, 52, will provide medical as well as organizational and regulatory leadership to the company as it moves forward with the development of AerovantTM for uncontrolled asthma and AerodermTM for severe atopic eczema. He has more than 20 years of experience in pulmonary research and product development.

"Tunde has a wealth of experience in the planning and implementation of clinical development programs for pulmonary drugs," said Mark Perry, Aerovance's president and chief executive officer. "He will focus on advancing Aerovant through clinical development, beginning with our upcoming Phase IIb clinical trial in patients living with uncontrolled asthma, while further developing Aerovance's pipeline."

Prior to joining the company, Dr. Otulana worked with Aradigm Corp., where he most recently served as senior vice president, development, and chief medical officer. At Aradigm, his responsibilities included the management of all clinical development, regulatory affairs, QA & QC, and R&D activities for respiratory specialty pharmaceutical products. Prior to Aradigm, he was a medical reviewer and team leader at the Division of Pulmonary Drug Products Center for the Drug Evaluation & Research of the U.S. Food and Drug Administration (FDA). Dr. Otulana is a practicing pulmonologist and has published numerous articles in peer-reviewed journals, most recently in the field of pulmonary delivery of therapeutics.

"I am excited to be joining the Aerovance team as the company advances its unique pipeline to meet significant unmet medical needs in the field of allergy and pulmonary medicine," said Dr. Otulana. "Aerovant and Aeroderm represent a new class of compounds which, if successful in development, will provide new tools for physicians in the management of intractable severe asthma and atopic dermatitis respectively, in millions of patients."

Aerovant is a recombinant human IL-4 variant that is a potent inhibitor of IL-4R alpha, a shared component of both the IL-4 and IL-13 receptors. Aerovance acquired the worldwide rights to the drug candidate when the company was formed as a spin-out of Bayer Pharmaceuticals Corporation in 2004.

Aerovance Inc. is a Berkeley, Calif.-based biopharmaceutical company focused on the development and commercialization of breakthrough therapies for the treatment of respiratory and inflammatory diseases. For more information, visit www.aerovance.com.

Editor's Note: Photograph available on request

    Contact:    Andreas Marathovouniotis or David Schull
    Russo Partners
                212-845-4235 or 212-845-4271
                andreas.marathis@russopartnersllc.com
    david.schull@russopartnersllc.com

                Dave Happel
                Aerovance Inc.
                510-549-5525
                dave.happel@aerovance.com


'/>"/>
SOURCE Aerovance Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Aerovance Secures $20 Million in Debt Financing
2. Cephalon Appoints Sarma P. Duddu as General Manager and Vice President of Drug Delivery Technologies for CIMA LABS
3. January 2009 - Rahu Appoints David Greensmith to Non Executive Directo
4. EUCODIS Bioscience Appoints Thomas Fischer as Chief Financial Officer
5. Amylin Pharmaceuticals Appoints Vincent Mihalik Senior Vice President, Sales and Marketing and Chief Commercial Officer
6. Qforma Appoints Two New Executives
7. Cyntellect Appoints Former Millipore and BD Biosciences Executives to Head Up its Product Marketing Efforts
8. PAREXEL Appoints Josephine Hoppe to Chief Information Officer
9. Jennerex Appoints Samantha Miller as Vice President of Corporate Development
10. Cumberland Pharmaceuticals Appoints Lee Product Director
11. Genesis Pharmaceuticals Appoints KPMG to Help Develop a SOX 404 Compliance Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... A new ... rates in frozen and fresh in vitro fertilization (IVF) transfer cycles. ... to IVF success. , After comparing the results from the fresh and frozen ...
(Date:10/10/2017)... Philadelphia, PA (PRWEB) , ... October 10, 2017 ... ... University City Science Center’s FirstHand program has won a US2020 STEM Mentoring Award. ... accept the award for Excellence in Volunteer Experience from US2020. , US2020’s mission ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... process optimization firm for the life sciences and healthcare industries, announces a presentation ... San Francisco. , The presentation, “Automating GxP Validation for Agile Cloud Platforms,” will ...
(Date:10/9/2017)... , ... October 09, 2017 , ... At its national ... Christopher Stubbs, a professor in Harvard University’s Departments of Physics and Astronomy, has been ... a member of the winning team for the 2015 Breakthrough Prize in Fundamental physics ...
Breaking Biology Technology:
(Date:4/5/2017)... 2017  The Allen Institute for Cell Science today ... one-of-a-kind portal and dynamic digital window into the human ... first application of deep learning to create predictive models ... and a growing suite of powerful tools. The Allen ... future publicly available resources created and shared by the ...
(Date:3/30/2017)... , March 30, 2017  On April 6-7, 2017, ... the Genome hackathon at Microsoft,s headquarters in ... competition will focus on developing health and wellness apps ... Hack the Genome is the first hackathon ... The world,s largest companies in the genomics, tech and ...
(Date:3/27/2017)... 2017  Catholic Health Services (CHS) has been ... (HIMSS) Analytics for achieving Stage 6 on the ... In addition, CHS previously earned a place in ... electronic medical record (EMR). "HIMSS Analytics ... EMR usage in an outpatient setting.  This recognition ...
Breaking Biology News(10 mins):